RecruitingNot ApplicableNCT06292715
Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism
A Single-Arm Clinical Study Evaluating Microwave Ablation of the Spleen Combined With Splenic Artery Occlusion for Secondary Hypersplenism Treatment
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
35 participants
Start Date
Jan 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study assesses the effectiveness of microwave ablation of the spleen in conjunction with splenic artery occlusion for treating secondary hypersplenism.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- \. written informed consent signed prior to enrolment 2. age \> 18 years, both sexes 3.Patients with severe hypersplenism secondary to cirrhosis with clinical diagnosis, White blood cells \<3×109/L, and/or platelet \<50×109/L 4.Patients who have been repeatedly given drugs to raise white blood cells and platelets in clinical practice have poor effect 5.Mental problems such as clinical symptoms or anxiety in patients require interventional treatment for hypersplenism
Exclusion Criteria9
- Patients with any of the following are not eligible for enrollment in this study
- Coagulopathy or other blood disorders
- Recent use of anticoagulant drugs
- Severe hypertension and cardiac insufficiency
- Bone marrow aspiration results showed bone marrow suppression
- Combined with other spleen malignant diseases
- Severe skin infection at the puncture site
- Participated in other clinical studies within 2 months prior to the start of the study
- Patient or his/her authorized person is unwilling to sign a written informed consent form or unwilling to comply with the study protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREmicrowave ablation of the spleen
Ultrasound-guided percutaneous puncture for splenic ablation treatment
OTHERSplenic artery balloon implantation
Splenic artery balloon implantation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06292715